San Jose, CA March 7, 2016- Regional Medical Center of San Jose is now offering patients the first and only cardiac resynchronization therapy defibrillators (CRT-Ds) approved by the FDA for use with magnetic resonance imaging (MRI) scans. Designed to help the heart pump more effectively in a coordinated rhythm, CRT-Ds, such as implanted pacemakers, are used to treat heart failure and help reduce the risk of sudden cardiac arrest. Until now, however, patients with CRT-Ds have not been able to receive MRI scans because of the potential for a harmful interaction between the MRI and the device. With as many as 40 percent of CRT patients needing an MRI within four years of receiving a device,1 thousands of patients implanted with CRT-Ds have not had access to MRI scans when they needed them.
“Our heart team is excited to be leading the way in improving care for heart failure patients,” said Ngai Nguyen, MD, Medical Director of Regional’s Coronary Cath Labs. “Patients being treated for heart failure with these new MRI-conditional CRT-D devices will no longer be denied access to MRI scans, which can be critical for doctors to detect and treat other underlying, potentially life-threatening conditions.
One million people with heart failure are hospitalized each year in the U.S., and 25 percent of them will be re-hospitalized within 30 days. As a Stemi (heart-attack) Receiving Center, Regional treats thousands of heart patients every year.
“Heart Failure is the fastest growing cardiac condition in the aging population, said Regional CEO, Mike Johnson.” We expect that MRI compatible CRT’s will soon become the new standard of care for all heart patients. “
Allowing for MRI scans on any part of the body without positioning restrictions, the MRI-conditional CRT-Ds from Medtronic, including the Amplia MRI™ Quad CRT-D SureScan® and Compia MRI™ Quad CRT-D SureScan® systems are designed to optimize therapy delivery. Amplia MRI features the AdaptivCRT® algorithm, which has been shown to reduce a patient’s odds of a heart failure readmission within 30 days by 59 percent, 2 and reduce the risk of atrial fibrillation by 46 percent.3
Regional now offers a complete portfolio of implantable cardiac devices including CRT-Ds, implantable cardioverter defibrillators (ICDs), pacemakers and insertable cardiac monitors-all FDA approved for use with MRI scans-to provide care for patients with heart failure, life-threatening arrhythmias or those at risk of sudden cardiac arrest.
About Regional Medical Center of San Jose
Regional Medical Center of San Jose is a Level II designated and verified Trauma Center staffed by in-house specialists 24/7/365. The hospital provides a host of technologically-advanced services including Cardiovascular, Neuro, Orthopedic, Bariatric and General Surgery, Interventional Pulmonology, along with multi-organ Cancer Care, and services for Women and Children. Regional holds Joint Commission advanced certification as a Comprehensive Stroke Center and a Get with the Guidelines- Stroke Gold Plus Performance Achievement Award from the American Heart Association/American Stroke Association. It is a certified Chest Pain Center, Certified Atrial Fibrillation Program, county-designated STEMI (heart attack) Receiving Center, ACoS accredited Community Cancer Center, designated Lung Cancer Screening Center, a member of Extracorporeal Life Support Organization (ECMO) and is certified by The Joint Commission in Sepsis care. Regional is a recipient of Healthgrades 2015 Distinguished Hospital Award for Clinical Excellence and has also been awarded several clinical and program awards from Healthgrades. The hospital has also been recognized by U.S. News and World Report and The Joint Commission as a top performing hospital. For more information, visit: www.regionalmedicalsanjose.com.
1 Medtronic data on file 2015: Data from MarketScan® 2012 Commercial and Medicare Database. Truven Health Analytics.
2 Starling RC, Krum H, Bril S, Tsintzos SI, Rogers T, Hudnall JH, Martin DO. Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence from the Adaptive CRT Trial, JACC: Heart Failure (2015), doi: 10.1016/j.chf.2015.03.001.
3 Martin D, et al. Clinical Outcomes with Adaptive Cardiac Resynchronization Therapy: Long-term Outcomes of the Adaptive CRT Trial. HFSA Late Breakers. September 23, 2013.